<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Schrodinger Inc — News on 6ix</title>
<link>https://6ix.com/company/schrodinger-inc</link>
<description>Latest news and press releases for Schrodinger Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/schrodinger-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835be2078dffbe2df117810.webp</url>
<title>Schrodinger Inc</title>
<link>https://6ix.com/company/schrodinger-inc</link>
</image>
<item>
<title>Schrödinger to Announce First Quarter 2026 Financial Results on May 5</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-to-announce-first-quarter-2026-financial-results-on-may-5</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-to-announce-first-quarter-2026-financial-results-on-may-5</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, April 21, 2026--Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.</description>
</item>
<item>
<title>Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive</description>
</item>
<item>
<title>Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25</title>
<link>https://6ix.com/company/schrodinger-inc/news/schr-dinger-announce-fourth-quarter-133000808</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schr-dinger-announce-fourth-quarter-133000808</guid>
<pubDate>Wed, 11 Feb 2026 13:30:00 GMT</pubDate>
<description>NEW YORK, February 11, 2026--Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.</description>
</item>
<item>
<title>Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities</title>
<link>https://6ix.com/company/schrodinger-inc/news/schr-dinger-provides-progress-across-133000437</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schr-dinger-provides-progress-across-133000437</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>NEW YORK, January 12, 2026--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery.</description>
</item>
<item>
<title>Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-partners-lilly-make-tunelab-platform-available-livedesign-2026-01-09</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-partners-lilly-make-tunelab-platform-available-livedesign-2026-01-09</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and</description>
</item>
<item>
<title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 15, 2025, the company granted restricted stock units (RSUs) with</description>
</item>
<item>
<title>Schrödinger to Present at Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-present-jefferies-london-healthcare-conference-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-present-jefferies-london-healthcare-conference-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London</description>
</item>
<item>
<title>Schrödinger Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-third-quarter-2025-financial-results-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-third-quarter-2025-financial-results-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc.</description>
</item>
<item>
<title>Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger</title>
<link>https://6ix.com/company/schrodinger-inc/news/copernic-catalysts-announces-achievement-of-ammonia-catalyst-milestone-in-research-collaboration-with-schrodinger</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/copernic-catalysts-announces-achievement-of-ammonia-catalyst-milestone-in-research-collaboration-with-schrodinger</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., October 30, 2025--Copernic Catalysts, Inc. (Copernic) today announced that, in collaboration with Schrödinger, Inc. (Nasdaq: SDGR), the companies have surpassed the final technical milestone for their jointly-developed ammonia synthesis catalyst, branded NeptuneTM. The Neptune catalyst demonstrated an ammonia yield that was over two times higher than that of competing catalysts under real-world reactor environments, achieving the success criteria outlined in the collaboration a</description>
</item>
<item>
<title>Schrödinger to Announce Third Quarter 2025 Financial Results on November 5</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-announce-third-quarter-2025-financial-results-november-5-2025-10-22</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-announce-third-quarter-2025-financial-results-november-5-2025-10-22</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the</description>
</item>
<item>
<title>Schrödinger to Present at Morgan Stanley Global Healthcare Conference</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-present-morgan-stanley-global-healthcare-conference-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-present-morgan-stanley-global-healthcare-conference-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd</description>
</item>
<item>
<title>Schrödinger Announces Discontinuation of SGR-2921 Program</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-announces-discontinuation-sgr-2921-program-2025-08-14</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-announces-discontinuation-sgr-2921-program-2025-08-14</guid>
<pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7</description>
</item>
<item>
<title>Schrödinger Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/schrodinger-inc/news/schr-dinger-reports-second-quarter-200500943</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schr-dinger-reports-second-quarter-200500943</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>NEW YORK, August 06, 2025--Schrödinger today announced financial results for the quarter ended June 30, 2025.</description>
</item>
<item>
<title>Schrödinger to Announce Second Quarter 2025 Financial Results on August 6</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-announce-second-quarter-2025-financial-results-august-6-2025-07-25</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-announce-second-quarter-2025-financial-results-august-6-2025-07-25</guid>
<pubDate>Fri, 25 Jul 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the</description>
</item>
<item>
<title>Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target</title>
<link>https://6ix.com/company/schrodinger-inc/news/ajax-therapeutics-and-schrodinger-expand-research-collaboration-include-additional</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/ajax-therapeutics-and-schrodinger-expand-research-collaboration-include-additional</guid>
<pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
<description>NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive</description>
</item>
<item>
<title>Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-receives-fast-track-designation-sgr-1505-treatment-relapsed-refractory</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-receives-fast-track-designation-sgr-1505-treatment-relapsed-refractory</guid>
<pubDate>Fri, 27 Jun 2025 04:00:00 GMT</pubDate>
<description>Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq:</description>
</item>
<item>
<title>Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-encouraging-initial-phase-1-clinical-data-sgr-1505-eha-annual</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-encouraging-initial-phase-1-clinical-data-sgr-1505-eha-annual</guid>
<pubDate>Thu, 12 Jun 2025 04:00:00 GMT</pubDate>
<description>SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory</description>
</item>
<item>
<title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-newly</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-newly</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company’s newly appointed EVP,</description>
</item>
<item>
<title>Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-expands-executive-leadership-team-appointment-mannix-aklian-chief</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-expands-executive-leadership-team-appointment-mannix-aklian-chief</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as</description>
</item>
<item>
<title>Schrödinger to Present at Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/schrodinger-inc/news/schrodinger-present-jefferies-global-healthcare-conference-2025-05-22</link>
<guid isPermaLink="true">https://6ix.com/company/schrodinger-inc/news/schrodinger-present-jefferies-global-healthcare-conference-2025-05-22</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global</description>
</item>
</channel>
</rss>